Cartesian Therapeutics, Inc.
NASDAQ: RNAC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carsten Brunn
- Employees
- 75
- Headquarters
- Frederick, United States
- IPO year
- 2016
- Market cap
- $283.2M
- Website
- https://cartesiantherapeutics.com
Loading RNAC…
Loading profile data…Frequently asked questions about RNAC
What does Cartesian Therapeutics, Inc. (RNAC) do?
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b cli...
Where does RNAC trade?
Cartesian Therapeutics, Inc. (RNAC) trades on the NASDAQ.
What sector is RNAC in?
Cartesian Therapeutics, Inc. (RNAC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cartesian Therapeutics, Inc.?
Carsten Brunn is the chief executive officer of Cartesian Therapeutics, Inc. (RNAC).
Where is Cartesian Therapeutics, Inc. headquartered?
Cartesian Therapeutics, Inc. is headquartered in United States.
Does RNAC pay a dividend?
Cartesian Therapeutics, Inc. (RNAC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RNAC go public?
Cartesian Therapeutics, Inc. (RNAC) completed its initial public offering in 2016.